RT @BldCancerDoc: 👍 editorial Dr Estey on new Rx for #AML “(1) stereotyped criteria for statistical significance and power ... (2) conflat…
RT @TaylorJ_MD: Totally agree- no complacency here @SylvesterCancer @umiamimedicine #leusm #AML #leukemia https://t.co/PHnO6XClAq https://t…
RT @Anand_88_Patel: In an editorial for the journal Leukemia Dr. Estey discusses whether new therapies in AML have impacted long-term outco…
In an editorial for the journal Leukemia Dr. Estey discusses whether new therapies in AML have impacted long-term outcomes in meaningful ways along with interpretation of statistical significance vs medical benefit https://t.co/M0eNbKgn7J
RT @BldCancerDoc: 👍 editorial Dr Estey on new Rx for #AML “(1) stereotyped criteria for statistical significance and power ... (2) conflat…
RT @drjgauthier: After all these years... Dr. Estey remains a Bayesian at heart... 😄 1993 https://t.co/0lvc2Iwp1l 1995 https://t.co/YYuotqL…
After all these years... Dr. Estey remains a Bayesian at heart... 😄 1993 https://t.co/0lvc2Iwp1l 1995 https://t.co/YYuotqLFA8 Time for primetime for Bayesian clinical trial designs? 😉 https://t.co/Q5ENeK8D98
RT @DrMarcosdelima: New treatments for acute myeloid leukemia: how much has changed? | Leukemia https://t.co/xd9pGJ2guf
RT @BldCancerDoc: 👍 editorial Dr Estey on new Rx for #AML “(1) stereotyped criteria for statistical significance and power ... (2) conflat…
RT @AaronGoodman33: Despite the many new (expensive) drugs approved for AML, outcomes have not changed much for patients living AML. Lets…
RT @AaronGoodman33: Despite the many new (expensive) drugs approved for AML, outcomes have not changed much for patients living AML. Lets…
RT @BldCancerDoc: 👍 editorial Dr Estey on new Rx for #AML “(1) stereotyped criteria for statistical significance and power ... (2) conflat…
RT @DrMarcosdelima: New treatments for acute myeloid leukemia: how much has changed? | Leukemia https://t.co/xd9pGJ2guf
RT @BldCancerDoc: 👍 editorial Dr Estey on new Rx for #AML “(1) stereotyped criteria for statistical significance and power ... (2) conflat…
RT @AaronGoodman33: Despite the many new (expensive) drugs approved for AML, outcomes have not changed much for patients living AML. Lets…
RT @AaronGoodman33: Despite the many new (expensive) drugs approved for AML, outcomes have not changed much for patients living AML. Lets…
RT @Dr_AmerZeidan: No one else aside from dr Estey can masterfully cover 1) how many researchers & regulators worship p-value of 0.05; 2) c…
RT @Dr_AmerZeidan: Spot on by dr Estey-“Hopefully the publicity surrounding the recently approved drugs will not blind people to their rela…
RT @BldCancerDoc: 👍 editorial Dr Estey on new Rx for #AML “(1) stereotyped criteria for statistical significance and power ... (2) conflat…
RT @AaronGoodman33: Despite the many new (expensive) drugs approved for AML, outcomes have not changed much for patients living AML. Lets…
RT @BldCancerDoc: 👍 editorial Dr Estey on new Rx for #AML “(1) stereotyped criteria for statistical significance and power ... (2) conflat…
RT @DrMarcosdelima: New treatments for acute myeloid leukemia: how much has changed? | Leukemia https://t.co/xd9pGJ2guf
RT @AaronGoodman33: Despite the many new (expensive) drugs approved for AML, outcomes have not changed much for patients living AML. Lets…
Despite the many new (expensive) drugs approved for AML, outcomes have not changed much for patients living AML. Lets not forget it is 7+3, HiDAC, and allogeneic transplant that is curing patients with AML.
RT @BldCancerDoc: 👍 editorial Dr Estey on new Rx for #AML “(1) stereotyped criteria for statistical significance and power ... (2) conflat…
RT @DrMarcosdelima: New treatments for acute myeloid leukemia: how much has changed? | Leukemia https://t.co/xd9pGJ2guf
New treatments for acute myeloid leukemia: how much has changed? | Leukemia https://t.co/xd9pGJ2guf
Totally agree- no complacency here @SylvesterCancer @umiamimedicine #leusm #AML #leukemia https://t.co/PHnO6XClAq https://t.co/o2Dk7NECER
👍 editorial Dr Estey on new Rx for #AML “(1) stereotyped criteria for statistical significance and power ... (2) conflation between statistical significance and medical benefit, and (3) uncritical adoption of the phrase meaningful clinical benefit.” https
RT @XimeJordan: New treatments for acute myeloid leukemia: how much has changed? | Leukemia https://t.co/Q71KxVF6K9
New treatments for acute myeloid leukemia: how much has changed? | Leukemia https://t.co/Q71KxVF6K9
RT @Dr_AmerZeidan: Spot on by dr Estey-“Hopefully the publicity surrounding the recently approved drugs will not blind people to their rela…
No one else aside from dr Estey can masterfully cover 1) how many researchers & regulators worship p-value of 0.05; 2) conflation between statistical significance and medical benefit, & (3 uncritical adoption of the phrase meaningful clinical benef
Spot on by dr Estey-“Hopefully the publicity surrounding the recently approved drugs will not blind people to their relatively modest gains, lead physicians and patients with AML to complacency, and decrease accrual into new clinical trials”-Leukemia https
Just read this Comment paper in @LeukemiaJnl by Elihu Estey... https://t.co/4plh8SxtI8 I agree with most of what it says,... but cannot agree with lowering the bar to approve novel leukemia drugs... Just because you are thirsty, you won´t drink in a muddy
A great piece on #AML and the "meaningful clinical benefit" of the newly approved drugs... by the one and only Dr. Elihu Estey! #leusm #bmtsm #leukemia https://t.co/y46fLAbDKy
The advances are most welcome in #AML >>>New treatments for acute myeloid leukemia: how much has changed? | Leukemia #leusm https://t.co/mQSz75DIMs